Global tests of haemostasis in critically ill patients with severe sepsis syndrome compared to controls
|
|
- Cornelius Bruce
- 5 years ago
- Views:
Transcription
1 research paper Global tests of haemostasis in critically ill patients with severe sepsis syndrome compared to controls Peter W. Collins, 1 Luis I. Macchiavello, 2 Sarah J. Lewis, 1 Nichola J. Macartney, 1 Anton G. Saayman, 2 Roger Luddington, 3 Trevor Baglin 3 and George P. Findlay 2 1 Department of Haematology, School of Medicine, Cardiff University and University Hospital of Wales, Cardiff, 2 Department of Intensive Care Medicine, Cardiff University and University Hospital of Wales, Cardiff, and 3 Department of Haematology, Addenbrookes Hospital, Cambridge, UK Received 23 May 2006; accepted for publication 14 July 2006 Correspondence: Dr P. W. Collins, Department of Haematology, School of Medicine, Cardiff University and University Hospital of Wales, Heath Park, Cardiff CF14 4XW, UK. peter.collins@cardffandvale.wales.nhs.uk Summary Haemostatic changes in septic patients are complex, with both procoagulant and anticoagulant changes. Thirty-eight patients with severe sepsis and 32 controls were investigated by coagulation screens, individual factor assays, calibrated automated thrombography (CAT), whole blood low-dose-tissue factor activated (LD-TFA) Rotem and LD-TFA waveform analysis. Thirty-six of 38 patients had an abnormal coagulation screen. The mean levels of factors II,V(P <0Æ05), VII, X, XI and XII, antithrombin and protein C (P <0Æ01) was decreased in sepsis compared with controls. The mean factor VIII and fibrinogen level (P < 0Æ001) was increased. CAT in platelet rich and poor plasma showed a prolonged lag time (P < 0Æ02), decreased peak thrombin (P <0Æ02) and delayed time to peak thrombin (P <0Æ001) in sepsis patients, however, the endogenous thrombin potential was equivalent in sepsis and controls. In LD-TFA Rotem, septic patients had delayed clot times (P ¼ 0Æ04) but an increased maximum velocity of clot formation (P < 0Æ01) and area under the clot elasticity curve (P <0Æ01). LD-TFA waveform analysis showed a delayed onset time but an increased rate of clot formation (P <0Æ005). In conclusion, global tests of haemostasis suggest that in this patient group, activation of haemostasis is delayed but once initiated thrombin generation and clot formation are normal or enhanced. Keywords: global haemostasis, sepsis, thrombin generation, thromboelastography, thrombosis. Sepsis is associated with complex changes in haemostasis. In severe cases, disseminated intravascular coagulation (DIC) may lead to consumption of platelets and coagulation factors resulting in clinical bleeding, whilst in other situations a compensated consumptive coagulopathy may be present, with fibrinogen levels and platelet number preserved or raised (Dempfle, 2004). Altered levels of both procoagulant factors and anticoagulant proteins have been described in patients with sepsis syndrome (Hesselvik et al, 1989; Mavrommatis et al, 2000; Dempfle, 2004; Dhainaut et al, 2005). Some changes, such as decreased levels of coagulation factors, predispose the patient to bleeding whilst others, such as raised factor VIII and fibrinogen and decreased levels of protein C and antithrombin, induce a prothrombotic state. Critically ill patients with sepsis syndrome often develop multi-organ organ failure. This complication has a complex pathophysiology but is thought to be partly due to microvascular thrombosis (Dixon, 2004). This hypothesis is indirectly supported by studies showing that patients with sepsis have increased markers of activation of haemostasis, such as d-dimer, prothrombin fragment and thrombin antithrombin complexes (TAT) (Gando et al, 1998; Mavrommatis et al, 2000; Amaral et al, 2004). Improved assessment of the balance between anticoagulant and prothrombotic changes may aid understanding of haemostatic changes associated with sepsis syndrome, give insight into the pathogenesis of multi-organ failure and ultimately aid the clinical management of patients. Current concepts of haemostasis support the view that haemostasis is activated through low concentrations of tissue factor (Mann et al, 2003; Roberts et al, 2004) and this has been confirmed in in vivo models of sepsis (Taylor et al, 1991). It is also thought that the rate of clot formation, and in particular the rate of thrombin generation, is crucial for formation of a stable fibrin clot (Roberts et al, 2004). Routine coagulation screens are often prolonged in critically ill patients with sepsis syndrome (Dempfle, 2004). However, there is debate about the doi: /j x Journal Compilation ª 2006 Blackwell Publishing Ltd, British Journal of Haematology, 135,
2 Global tests of haemostasis in sepsis utility of these tests in assessing haemostasis (Mannucci, 2006; Reverter, 2006) and coagulation screens appear not to accurately reflect a patient s risk of bleeding (Segal & Dzik, 2005). This may be because the endpoint of these assays is early in the haemostatic process or because they are initiated by high concentrations of tissue factor or contact activators that do not reflect the physiological situation. Despite these shortcomings, prolonged coagulation screens are often treated with infusion of fresh frozen plasma (FFP), even though individual coagulation factor levels are often not significantly reduced (Chowdhury et al, 2004). There has been recent interest in the role of global tests of haemostasis, such as thrombin generation assays, in the investigation of both acquired and congenital haemostatic defects (Al Dieri et al, 2002; Hemker et al, 2003; Luddington & Baglin, 2004). A thromboelastographic method, activated by low concentration tissue factor and measured using the Rotem Ò machine, has also been described (Sorensen et al, 2003). Updated software enabled the standard clot elasticity trace to be differentiated to give a velocity of clot strengthening, and the area under this curve gives a measure of the total amount of increasing clot strength (Sorensen et al, 2003). A third test is described here, which activates haemostasis through low concentrations of tissue factor in the presence of thrombomodulin and measures rate of fibrin clot formation using the first derivative of the MDA waveform. Assays that are activated by low concentrations of tissue factor are susceptible to contact activation (Luddington & Baglin, 2004). Although activation of contact factors may occur in sepsis, depletion of these factors will not affect in vivo haemostasis and assays that are contact-activated may be misleading in the setting of sepsis. In the assays presented here, we therefore inhibited contact activation with corn trypsin inhibitor (CTI). We report the results of routine coagulation tests and three global haemostatic assays in critical ill patients with severe sepsis syndrome. Materials and methods Subjects The study was reviewed by the South East Wales Research Ethics Committee and the Cardiff and Vale NHS Trust Research and Development Office. A cohort of 32 anonymised, adult normal controls was recruited and compared with a cohort of 39 adult critically ill patients with severe sepsis syndrome. The patient cohort was recruited from the general intensive care unit (ICU) and were aged 18 years or older. Severe sepsis syndrome was defined according to standard criteria; temperature >38Æ5 C or <35 C, white blood cell count > /l or < /l, respiratory rate >20 breaths/min or patient dependent on ventilation, heart rate >90 beats/min and suspected or proven infection, with organ dysfunction, hypoperfusion or hypotension (American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference, 1992). No patients were bleeding or receiving an infusion of activated protein C or therapeutic heparin at the time of sample collection. Patients, or next-of-kin, gave written informed consent. Patients who were unable to give consent were retrospectively informed of the study after recovery and given the opportunity to withdraw. Basic demographic data as well as 28-day mortality was collated from the ICU database. Blood samples Blood was obtained from patients via a radial arterial line. The first 20 ml of blood was drawn into a syringe and discarded to avoid heparin contamination. Measurement of anti-xa heparin levels in the samples showed a raised level in one patient who was excluded from subsequent analyses. A full blood count was performed (Haribo ABX Pentra 120; Haribo ABX, Montpellier, France). Further blood was drawn into a fresh syringe and immediately anticoagulated with 0Æ109 mol/l trisodium citrate (Sigma, Poole, UK) and 20 lg/ml CTI (Cambridge BioScience, Cambridge, UK). Two further 4Æ5 ml aliquots of citrated blood were collected. The samples were centrifuged at 83 g for 10 min at room temperature. The supernatant platelet rich plasma (PRP) was collected and the samples re-spun at 1168 g for a further 15 min at room temperature. The plasma supernatant was removed and re-spun at 1168 g to give double-spun platelet poor plasma (PPP). The PRP platelet count was measured (Haribo ABX Pentra 120) and diluted with autologous PPP to give a count of /l. In samples where the platelet count in the PRP was < /l, no adjustment was made. Further PPP samples (not taken into CTI) were aliquoted and frozen at )80 C for later analysis of prothrombin time (PT), activated partial thromboplastin time (aptt), TT, fibrinogen, factors II, V, VII, VIII, IX, X, XI and XII, protein C and antithrombin using the MDA II analyser (biomérieux UK Ltd, Basingstoke, UK) according to manufacturer s protocols. These assays are externally quality controlled through the UK National External Quality Assessment Schemes. Calibrated automated thrombography Immulon 2HB 96-well round bottomed microtitre plates were used to carry out the fluorogenic reaction. Thrombin generation was measured using a Fluoroskan Ascent plate reader (ThermoLabsystems, Helsinki, Finland) using excitation and emission spectra of 390 and 460 nm, respectively. Fluorogenic substrate (Z Gly Gly Arg AMC) was obtained from Bachem (St Helens, UK) and was prepared using the method described (Hemker et al, 2003). Dimethyl sulphoxide and bovine serum albumin (BSA) were obtained from Sigma (Poole, UK), HEPES, NaCl and CaCl 2 were obtained from VWR International (Lutterworth, UK). The phospholipid vesicles were constructed by an extrusion method and consisted of phosphatidylserine, phosphatidylethanolamine and phosphatidylcholine. Journal Compilation ª 2006 Blackwell Publishing Ltd, British Journal of Haematology, 135,
3 Peter W Collins et al Eighty ll of sample (PRP or PPP) was incubated with 20 ll of tissue factor solution, Innovin (Sysmex UK Ltd, Milton Keynes, UK) ph 7Æ35 diluted in HEPES/NaCl buffer, to give a final concentration of 5 pm for PPP and 0Æ5 pm for PRP as previously described (Hemker et al, 2003). Each sample was measured in triplicate with a calibration well that contained 80 ll of PPP or PRP from the relevant patient and 20 ll of thrombin calibrator (600 nmol/l) supplied by Synapse BV, Maastricht, the Netherlands. The plate was warmed in the Fluoroskan for 5 min, followed by the addition of 20 ll of fluorogenic substrate per well. The fluorescent signal was then measured at 15 s intervals until the reaction was complete. The data was analysed using thrombinoscope TM software (Synapse BV, Maastricht, the Netherlands). Each plate contained a control aliquot of PPP, the inter-assay coefficient of variance was lag time 12%, endogenous thrombin potential (ETP) 8%, peak thrombin 8%, time to peak thrombin 10%. Low concentration tissue factor-activated thromboelastography Measurements were performed on a Rotem 05 Coagulation Analyser (Pentapharm Ò, Munich, Germany). All tests were performed in Rotem cup and pins. Blood samples were tested 30 min after venepuncture (Sorensen et al, 2003). Cup holders were prewarmed to 37 C. 300 ml of whole blood taken into CTI, final concentration 20 lg/ml, was dispensed into the sample cups according to the EXTEG program. Clotting was initiated by the addition of 20 ll 200 mmol/l CaCl 2 and tissue factor (Innovin) at final concentrations of 0Æ35 pmol/l as previously described (Sorensen et al, 2003). calcuro software (Pentapharm GmbH, Munich, Germany) was used to calculate derived parameters. As the whole blood nature of the assay makes quality assurance difficult, the inter-assay reproducibility was assessed using freeze-thaw PRP that was aliquoted and run with each sample. This gave a coefficient of variance of clot time 9%, mean clot firmness 4%, alpha angle 2%, maximum velocity 10%, time to maximum velocity 9% and area under the clot firmness curve 3%. Low concentration tissue factor-activated MDA waveform global haemostatic assay Measurements were performed on a MDAII coagulation analyser (biomérieux, Lyon, France). Briefly 50 ll of PPP taken into 20 lg/ml CTI was incubated at 37 C with 2 pmol/l tissue factor and 0Æ75 nmol/l Thrombomodulin (American Diagnostica Inc., Stamford, CT, USA) for 220 s. Clot formation was initiated by the addition of CaCl 2 (VWR International, Lutterworth, UK) containing 1 mmol/l phosphorylcholine (Sigma-Aldrich Co. Ltd, Gillingham, UK) and monitored at a wavelength of 460 nm. The maximum rate of fibrin polymerisation was calculated from the first derivative of the light transmittance (T) against time and is the value reported (Braun et al, 1997). Statistics The data were analysed using The Statistical Package for the Social Sciences (spss) version 12Æ1. Parameters measured on control samples were normally distributed; however, many parameters measured on patient samples were not (analysed by the Kolmogorov Smirnov test). Comparisons between patients and controls were therefore performed with a Mann Whitney U-test and correlations were performed using a Spearman rank test. P-values <0Æ05 were considered significant. Results Patients The patients were recruited from the general ICU if they fulfilled the criteria for severe sepsis syndrome (American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference, 1992). Patient characteristics at the time of enrolment into the study are shown in Table I. None of the patients was bleeding at the time of blood sampling. Routine coagulation tests and coagulation factor levels The patients with severe sepsis syndrome had abnormal coagulation screens compared with normal controls (Table II). Of the 38 patients with sepsis, 36 (95%) had an abnormal coagulation screen and 23 (60%) had either PT or aptt >1Æ5 times the midpoint of the normal range, a commonly used trigger for the use of FFP in patients undergoing operative procedures (American Society of Anesthesiologists Task Force on Blood Component Therapy, 1996). None of the patients had a low fibrinogen. The abnormal coagulation screens were caused by decreased levels of coagulation factors II, V, VII, X and XII leading to prolongation of the time to clot formation in these assays (Table II). In the 38 patients with sepsis, 12 (32%) had all haemostatically relevant coagulation factors within the normal range and only eight (21%) had one or more factor below a theoretic haemostatic threshold (<15 iu/dl for factor VII and Table I. Patient characteristics and outcome. Median (range) Age (years) 61 (19 82) APACHE II 18 (6 30) APACHE III 61 (26 94) SAPS II 43 (21 69) Number of organ failures 1 (0 4) Organ failure score 17 (6 36) Length of stay on ICU 11 (1 60) 28 day mortality 34% The clinical status of patients when recruited into the study is shown. APACHE, acute physiology and chronic health evaluation; SAPS, simplified acute physiology score; ICU, intensive care unit. 222 Journal Compilation ª 2006 Blackwell Publishing Ltd, British Journal of Haematology, 135,
4 Global tests of haemostasis in sepsis Table II. Routine coagulation tests and individual factor assays in patients with sepsis compared with controls. Control subjects, Mean (SD) Sepsis patients, Mean (SD) PT (s) 11Æ7 (0Æ5) 20Æ1 (5Æ9)** APTT (s) 27 (3Æ4) 50Æ1 (36Æ3)** Fibrinogen (g/l) 2Æ8 (0Æ57) 5Æ7 (2Æ6)** FII (iu/dl) 100 (12Æ1) 60 (30Æ2)** FV (iu/dl) 116 (22Æ9) 95 (56Æ4)* FVII (iu/dl) 130 (31Æ1) 55 (30Æ7)** FVIII (iu/dl) 107 (31Æ5) 257 (113)** FIX (iu/dl) 101 (16Æ5) 111 (51Æ8) FX (iu/dl) 123 (16Æ6) 72 (40Æ8)** FXI (iu/dl) 116 (15Æ7) 77 (40Æ7)** FXII (iu/dl) 125 (27Æ8) 52 (24Æ1)** Protein C (%) 127 (20) 63 (34Æ3)** Antithrombin (iu/dl) 103 (8) 63Æ1 (28Æ7)** C Reactive protein (mg/l) <6 181 (98Æ5) Albumin (g/l) Æ7 (7Æ4) The mean and SD for routine coagulation tests and individual coagulation factors and anticoagulant proteins are shown. C reactive protein and albumin were not performed on normal controls, the normal range stated is the local laboratory range. *P ¼ 0Æ03; **P <0Æ001. <30 iu/dl for other coagulation factors). There were 18 patients with a low level of factor XII, which does not contribute to the haemostatic risk but would have led to an abnormal aptt. In contrast, the mean factor IX level was not significantly reduced compared with normal controls. Factor IX was not below 30 iu/dl in any patients and was raised in 11 patients. Furthermore, factor VIII was significantly increased in the sepsis patients compared with normal controls (P < 0Æ001). Factor VIII was not reduced in any patients and was above the laboratory normal range (150 iu/dl) in 32 (84%) patients. Similarly, fibrinogen was increased (above 4 g/l) in 24 of the 38 (63%) patients. There was a lower mean level of the anticoagulant proteins antithrombin and protein C. In 20 (53%) patients, the level of protein C was below the normal range (<70 iu/dl) and in 25 (66%) patients, the antithrombin level was low (<75 iu/dl). The mean platelet count in the sepsis group was /l (range ) compared with /l (range ) for the controls. There was a strong correlation between the fibrinogen level and C reactive protein (CRP) (r ¼ 0Æ51, P <0Æ01) suggesting that the raised fibrinogen was secondary to an acute phase reaction. There was no correlation between factor VIII and CRP. Antithrombin has previously been suggested to be negatively correlated with an acute phase reaction (Niessen et al, 1997), but no correlation with CRP was observed in our study. Albumin correlated with factors II (r ¼ 0Æ67), V (r ¼ 0Æ52), VIII (r ¼ 0Æ42), IX (r ¼ 0Æ85), X (r ¼ 0Æ58), XI (r ¼ 0Æ73) and XII (r ¼ 0Æ6) (P <0Æ01), in keeping with these proteins being synthesised in the liver. Albumin also strongly correlated with a decreased antithrombin (r ¼ 0Æ69) and protein C (r ¼ 0Æ58) (P <0Æ01). Although almost all patients had abnormal coagulation screenings, the variable levels of procoagulant and anticoagulant proteins means that it was unclear whether an individual patient was at increased risk of bleeding during invasive procedures or of microvascular thrombosis predisposing to multi-organ failure. Global tests of haemostasis in this group of patients were performed. Thrombin generation assays Calibrated automated thrombography (CAT) was performed in PRP and PPP and the pattern of results was the same. In critically ill patients with sepsis compared with normal controls, the lag time to thrombin generation was prolonged, peak thrombin was decreased and time to peak thrombin prolonged. The mean total amount of thrombin generated in the group of patients with sepsis as measured by the ETP, however, was equivalent to normal controls (Table III). There was, however, a wide range of thrombin generation in the patient group and thrombocytopenia, leading to decreased platelet count in the PRP, was an important cause of decreased ETP. Representative thrombin generation in PRP and PPP is shown in Fig 1. These results suggest that, although some patients had a decreased ETP implying a potentially increased risk of bleeding, as a group, once activated, thrombin was generated in normal amounts. Table III. Calibrated automated thrombography in patients with sepsis compared with controls. Control subjects, mean (SD) Sepsis patients, mean (SD) PRP Lag time (min) 17 (8) 29 (22)* ETP (nmol/læmin) 1395 (488) 1334 (512) Peak thrombin (nmol/l) 76 (40) 56 (31)* Time to peak (min) 32 (12) 48 (27)** PPP Lag time (min) 2Æ4 (0Æ9) 5Æ0 (5Æ4)** ETP (nmol/læmin) 1681 (281) 1642 (452) Peak thrombin nmol/l 454 (100) 344 (146)** Time to peak (min) 4Æ2 (1Æ2) 6Æ7 (6Æ7)** The mean and SD of thrombin generation assays in platelet rich (PRP) and poor plasma (PPP) in patients compared with controls are shown. The prolongation of the lag times and time to peak thrombin generation suggest a delay in the activation of haemostasis but the normal endogenous thrombin potential (ETP) implies that once thrombin generation has been initiated a similar total amount of thrombin to normal is produced. *P <0Æ02; **P <0Æ001. Journal Compilation ª 2006 Blackwell Publishing Ltd, British Journal of Haematology, 135,
5 Peter W Collins et al (A) nmol/l thrombin (B) 120 nmol/l thrombin Minutes Minutes Fig 1. The variability of thrombin generation within the sepsis patient group. (A) Representative thrombin generation for four patients with sepsis (solid lines) compared with a control (dashed lines) in platelet poor plasma. (B) Representative thrombin generation studies for four different patients with sepsis (solid lines) compared with a control (dashed lines) in platelet rich plasma. Most patients had a delayed lag time (note different x-axis scales) but, once initiated, total thrombin generation, as defined by area under the thrombin generation curve, was equivalent to normal. However, some patients had markedly decreased thrombin generation, especially in platelet rich plasma. Low concentration tissue factor activated thromboelastography Compared with normal controls, critically ill patients with sepsis syndrome as a group had a prolonged time to initial clot formation (clot time). However, the alpha angle and mean clot firmness were increased. The first derivative of the clot firmness curve revealed an increased maximum velocity of clot formation and increased area under the clot firmness curve in patients compared with controls (Table IV). These results are similar to those derived from the thrombin generation assays in that there was a delay in activation of haemostasis but, once initiated, clot formation proceeded normally or was exaggerated. Low concentration tissue factor-activated MDA waveform assay The mean (SD) time to clot formation was 75Æ8 s (21Æ0) in the control patients compared with 97Æ4 s (36Æ9) in the sepsis group (P <0Æ01). The group of normal controls had a mean (SD) clot transmission velocity result of 0Æ99 (0Æ39)/Ts compared with the sepsis group 1Æ83 (0Æ54), P < 0Æ005. These results were again similar to the CAT and Rotem assays because they suggest that, as a group, the patients with severe Table IV. Low concentration tissue factor-activated thrombography in patients compared with controls. sepsis had delayed initiation of clot formation but once activated haemostasis was exaggerated. Discussion Control subjects, mean (SD) Sepsis patients, mean (SD) Clot time (s) 818 (271) 1163 (784)* Mean clot firmness (mm) 51 (12) 67 (17)*** Alpha angle ( ) 47 (15) 55 (21)** Maximum velocity (mm/s) 6Æ5 (3Æ0) 11Æ2 (7Æ5)** Time to maximum velocity (s) 1040 (334) 1042 (633) Area under clot firmness curve 51 (12) 62 (24)*** The mean and SD of each parameter is shown in patients with sepsis and controls. The prolonged clot time indicates a delay in initiation of haemostasis but the raised mean clot firmness, alpha angle, maximum velocity of clot formation and area under the clot firmness curve all support a procoagulant state. *P <0Æ05; **P <0Æ005; ***P <0Æ0005. The data reported here demonstrated that critically ill patients with sepsis syndrome have abnormal routine coagulation 224 Journal Compilation ª 2006 Blackwell Publishing Ltd, British Journal of Haematology, 135,
6 Global tests of haemostasis in sepsis screens and delayed initiation of haemostasis, as measured by three low concentration tissue factor-activated global haemostatic assays. These assays further showed that, once haemostasis was activated, the propagation and clot formation phase was either normal or enhanced. The three global haemostatic assays showed a similar pattern of results. The CAT assays demonstrated that, whilst initiation of thrombin generation was delayed and peak thrombin reduced, the total amount of thrombin, as measured by the ETP, was unchanged in the patients with sepsis compared with controls. Similarly, whilst the time to clot in the whole blood, low concentration tissue factor Rotem assay and the MDA waveform assay were also delayed, the rate of increasing fibrin clot elasticity and rate of clot formation was enhanced. The findings of this study may be explained by the measured levels of individual coagulation factors in the light of currently accepted models of haemostasis. Coagulation is thought to be activated through the tissue factor/factor VII pathway, which generates a small amount of thrombin, insufficient to clot fibrinogen, but required for the activation of factors V and VIII and expression of negatively charged phospholipids on platelets. The rapid burst of thrombin generation required to form a stable clot is then driven through the tenase complex of factor IXa and factor VIIIa and the prothrombinase complex of factor Xa and factor Va localised on the negatively charged phospholipid surface of activated platelets (Mann et al, 2003; Roberts et al, 2004). Activation of haemostasis in sepsis has been shown to be through the tissue factor pathway (Taylor et al, 1991; Levi et al, 2003). In the sepsis group of patients, it is likely that the decreased levels of factors VII, X and II led to a delay in the generation of sufficient initial thrombin to activate factors V and VIII and to stimulate expression of platelet phospholipids. The major components of the intrinsic pathway (factors IXa and VIIIa), however, were preserved or increased in sepsis patients and hence, once the cofactors had been activated, thrombin and fibrin generation proceeded normally or was enhanced. This mechanism also explains the prolonged PT and aptt tests, which are sensitive to the initiation rather than the propagation phase of haemostasis. Measurement of individual coagulation factors and anticoagulants in this study demonstrated a pattern similar to those previously reported (Hesselvik et al, 1989). The procoagulant factors II, V, VII, X and XI as well as the anticoagulant factors antithrombin and protein C, were decreased compared with normal. The level of these factors correlated with serum albumin, suggesting that hepatic dysfunction as well as consumption played a role. Some coagulation factors, such as factor VIII and fibrinogen, were increased whilst factor IX was stable. The raised fibrinogen (but not factor VIII) correlated with CRP confirming that the increase was the result of an acute phase reaction. It is unclear what effect the combined changes in individual coagulation factors and anticoagulant have on global haemostasis, especially as some patients were also thrombocytopenic. As a result, it was not clear from the measurement of individual factors whether patients were at increased risk of bleeding, thrombosis or both. It is possible that some parameters of the global haemostatic tests may give information about the balance between pro- and anti-coagulant changes. The low concentration tissue factoractivated MDA waveform assay described here, for example, measures the rate of fibrin clot formation in PPP in the presence of thrombomodulin. This means the assay is sensitive to the protein C concentration in the sample in addition to the procoagulant clotting factors. The CAT and Rotem assays are not sensitive to the reduced levels of antithrombin and protein C and would underestimate the procoagulant state in patients. In routine clinical practice, clinicians rely on the PT and aptt to assess a patient s haemostatic status. Prolongation of these assays is interpreted as evidence of an anticoagulated state and FFP is often infused, particularly at the time of invasive procedures. This contrasts with previous findings of raised markers of activation of haemostasis, such as prothrombin fragment and TAT, in sepsis syndrome (Gando et al, 1998; Mavrommatis et al, 2000; Amaral et al, 2004). We have previously shown that abnormal coagulation screening tests are not a reliable guide to coagulation factors levels in critically ill patients (Chowdhury et al, 2004) and there continues to be a debate regarding the utility of coagulation screens to predict bleeding during invasive procedures in the context of hepatic dysfunction (Segal & Dzik, 2005; Mannucci, 2006; Reverter, 2006). This issue was further highlighted by our finding that factor XII was the most commonly reduced individual coagulation factor in the cohort of septic patients as previously reported (Hesselvik et al, 1989). Reduced factor XII is an important cause of a prolonged aptt, but it is not required for haemostasis and so the prolongation of the aptt related to a low factor XII is misleading and likely to be one of the major reasons why the aptt is of limited utility in assessing clinical bleeding risk in septic patients. The prolonged coagulation screening tests and the delayed initiation of haemostasis demonstrated by the three global tests probably reflect similar processes. If this is the case then the initiation time in the global assays may also have limited utility in assessing an individual patient s risk of bleeding and need for blood product support. It is possible that other parameters measured on the global assays that assess the propagation phase of haemostasis may be more useful. Although in our study the septic patients, as a group, had some results suggestive of a prothrombotic state, individuals had parameters of global haemostasis below the normal range, which may indicate an increased risk of bleeding during invasive procedures. The present study aimed to establish the effect of sepsis on global haemostatic assays. It did not aim to link these results to either bleeding or thrombotic complications in these patients and patients who were bleeding were not recruited into the study. The role of these assays in the management of patients remains to be defined. Further studies are underway to link Journal Compilation ª 2006 Blackwell Publishing Ltd, British Journal of Haematology, 135,
7 Peter W Collins et al clinical relevant bleeding endpoints to global assays of haemostasis in this patient population. Baseline levels and dynamic changes in haemostatic factors have been associated with outcome in critically ill patients with sepsis and used as evidence to support a pathophysiological link between coagulation abnormalities and multi-organ failure (Dhainaut et al, 2005). Biphasic clot waveform has also been shown to predict clinical outcome in sepsis (Toh et al, 2003). There were too few patients included in this study to investigate whether any parameters measured were predictive of prognosis or outcome. We conclude that global assays activated by low concentrations of tissue factor show that critically ill patients with sepsis have delayed activation of haemostasis but, once initiated, thrombin and clot formation are normal or enhanced. The results may help to explain why routine coagulation screen tests poorly predict bleeding in sepsis. Whether global assays will be useful in clinical practice will only be established once they are linked to relevant end points of bleeding, end organ failure and clinical outcomes. Competing interests The Rotem machine and consumables used in this study were supplied to the haematology department in Cardiff without charge by Sysmex UK Limited, the company that was marketing the instrument in the UK at the time of the study. Acknowledgements The study was supported by a Research and Development grant from the Cardiff and Vale NHS Trust. Laboratory tests were performed by N. Macartney, G. Florou J. Knippings, E. Stephenson, L. Hathaway and R. Davies. S. Lees helped to establish the CAT assays. Anthony Wilkes contributed to the statistical analysis of the data. References Al Dieri, R., Peyvandi, F., Santagostino, E., Giansily, M., Mannucci, P.M., Schved, J.F., Beguin, S. & Hemker, H.C. (2002) The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thrombosis and Haemostasis, 88, Amaral, A., Opal, S.M. & Vincent, J.-L. (2004) Coagulation in sepsis. Intensive Care Medicine, 30, American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Critical Care Medicine, 20, American Society of Anesthesiologists Task Force on Blood Component Therapy (1996) Practice guidelines for blood component therapy: a report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology, 84, Braun, P., Givens, T.B., Stead, A.G., Beck, L.R., Gooch, S.A., Swan, R.J. & Fischer, T.J. (1997) Properties of optical data from activated partial thromboplastin time and prothrombin time assays. Thrombosis and Haemostasis, 78, Chowdhury, P., Saayman, A.G., Paulus, U., Findlay, G.P. & Collins, P.W. (2004) Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. British Journal of Haematology, 125, Dempfle, C.-E. (2004) Coagulopathy of sepsis. Thrombosis and Haemostasis, 91, Dhainaut, J.F., Shorr, A.F., Macias, W.L., Kollef, M.J., Levi, M., Reinhart, K. & Nelson, D.R. (2005) Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure. Critical Care Medicine, 33, Dixon, B. (2004) The role of microvascular thrombosis in sepsis. Anaesthesia and Intensive Care, 32, Gando, S., Nanzaki, S., Sasaki, S., Aoi, K. & Kemmotsu, O. (1998) Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock. Critical Care Medicine, 26, Hemker, H.C., Giesen, P., Al Dieri, R., Regnault, V., de Smedt, E., Wagenvoord, R., Lecompte, T. & Béguin, S. (2003) Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiology of Haemostasis and Thrombosis, 33, Hesselvik, J.F., Blomback, M., Brodin, B. & Maller, R. (1989) Coagulation, fibrinolysis, and kallikrein systems in sepsis: relation to outcome. Critical Care Medicine, 17, Levi, M., Keller, T.T., van Gorp, E., ten Cate, H. (2003) Infection and inflammation and the coagulation system. Cardiovascular Research, 60, Luddington, R. & Baglin, T. (2004) Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition. Journal of Thrombosis and Haemostasis, 11, Mann, K.G., Brummel, K. & Butenas, S. (2003) What is all the thrombin for? Journal of Thrombosis and Haemostasis, 1, Mannucci, P.M. (2006) Abnormal haemostasis tests and bleeding in chronic liver disease: are they related? No. Journal of Thrombosis and Haemostasis, 4, Mavrommatis, A.C., Theodoridis, T., Orfanidou, A., Roussos, C., Christopoulou-Kokkinou, V. & Zakynthinos, S. (2000) Coagulation system and platelets are fully activated in uncomplicated sepsis. Critical Care Medicine, 28, Niessen, R.W., Lamping, R.J., Jansen, P.M., Prins, M.H., Peters, M., Taylor, F.B. Jr, de Vijlder, J.J., ten Cate, J.W., Hack, C.E. & Sturk, A. (1997) Antithrombin acts as a negative acute phase protein as established with studies on HepG2 cells and in baboons. Thrombosis and Haemostasis, 78, Reverter, J.C. (2006) Abnormal haemostasis tests and bleeding in chronic liver disease: are they related? Yes. Journal of Thrombosis and Haemostasis, 4, Roberts, H.R., Monroe, D.M. & Escobar, M.A. (2004) Current concepts of hemostasis: implications for therapy. Anesthesiology, 100, Segal, J.B. & Dzik, W.H. (2005) Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion, 45, Sorensen, B., Johansen, P., Christiansen, K., Woelke, M. & Ingerslev, J. (2003) Whole blood coagulation thrombelastographic profiles 226 Journal Compilation ª 2006 Blackwell Publishing Ltd, British Journal of Haematology, 135,
8 Global tests of haemostasis in sepsis employing minimal tissue factor activation. Journal of Thrombosis and Haemostasis, 1, Taylor, F.B. Jr, Chang, A., Ruf, W., Morrissey, J.H., Hinshaw, L., Catlett, R., Blick, K. & Edgington, T.S. (1991) Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circulatory Shock, 33, Toh, C.H., Ticknor, L.O., Downey, C., Giles, A.R., Paton, R.C. & Wenstone, R. (2003) Early identification of sepsis and mortality risks through simple, rapid clot-waveform analysis. Implications of lipoprotein-complexed C reactive protein formation. Intensive Care Medicine, 29, Journal Compilation ª 2006 Blackwell Publishing Ltd, British Journal of Haematology, 135,
Determination of APTT factor sensitivity the misguiding guideline
International Journal of Laboratory Hematology ORIGINAL ARTICLE The Official journal of the International Society for Laboratory Hematology INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY Determination
More informationIntroduction to coagulation and laboratory tests
Introduction to coagulation and laboratory tests Marc Jacquemin Special Haemostasis Laboratory Center for Molecular and Vascular Biology University of Leuven Coagulation in a blood vessel: fibrin stabilises
More informationEDUCATIONAL COMMENTARY DISSEMINATED INTRAVASCULAR COAGULATION
EDUCATIONAL COMMENTARY DISSEMINATED INTRAVASCULAR COAGULATION Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
More informationCoagulation, Haemostasis and interpretation of Coagulation tests
Coagulation, Haemostasis and interpretation of Coagulation tests Learning Outcomes Indicate the normal ranges for routine clotting screen and explain what each measurement means Recognise how to detect
More informationManaging Coagulopathy in Intensive Care Setting
Managing Coagulopathy in Intensive Care Setting Dr Rock LEUNG Associate Consultant Division of Haematology, Department of Pathology & Clinical Biochemistry Queen Mary Hospital Normal Haemostasis Primary
More informationL iter diagnostico di laboratorio nelle coagulopatie congenite emorragiche
L iter diagnostico di laboratorio nelle coagulopatie congenite emorragiche Armando Tripodi Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Dept. of Clinical Sciences and Community Health University
More informationPrimary Exam Physiology lecture 5. Haemostasis
Primary Exam Physiology lecture 5 Haemostasis Haemostasis Body s response for the prevention and cessation of bleeding. Broadly consists of: Primary Haemostasis - vascular spasm and platlet plug formation
More informationTRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006
TRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006 CTU blood product transfusion guidelines 2006 1 Summary of guidelines RED CELLS (10-15ml/kg) This applies to ward patients / icu patients who are stable.
More informationJohn Davidson Consultant in Intensive Care Medicine Freeman Hospital, Newcastle upon Tyne
John Davidson Consultant in Intensive Care Medicine Freeman Hospital, Newcastle upon Tyne Overview of coagulation Testing coagulation Coagulopathy in ICU Incidence Causes Evaluation Management Coagulation
More informationDIC. Bert Vandewiele Fellow Critical Care 23 May 2011
DIC Bert Vandewiele Fellow Critical Care 23 May 2011 Dissiminated Intravascular Coagulopathie 11/3/2011 Dr. Bert Vandewiele 2 Dissiminated Intravascular Coagulopathie = Consumption coagulopathie = Defibrination
More informationProthrombin Complex Concentrate- Octaplex. Octaplex
Prothrombin Complex Concentrate- Concentrated Factors Prothrombin Complex Concentrate (PCC) 3- factor (factor II, IX, X) 4-factor (factors II, VII, IX, X) Activated 4-factor (factors II, VIIa, IX, X) Coagulation
More informationDiagnosis of hypercoagulability is by. Molecular markers
Agenda limitations of clinical laboratories to evaluate hypercoagulability and the underlying cause for thrombosis what is the INR the lupus anticoagulant and the antiphospholipid antibody syndrome hassouna
More informationMANAGEMENT OF COAGULOPATHY AFTER TRAUMA OR MAJOR SURGERY
MANAGEMENT OF COAGULOPATHY AFTER TRAUMA OR MAJOR SURGERY 19th ANNUAL CONTROVERSIES AND PROBLEMS IN SURGERY Thabo Mothabeng General Surgery: 1 Military Hospital HH Stone et al. Ann Surg. May 1983; 197(5):
More informationDisseminated Intravascular Coagulation. M.Bahmanpour MD Assistant professor IUMS
به نام خدا Disseminated Intravascular Coagulation M.Bahmanpour MD Assistant professor IUMS Algorithm for Diagnosis of DIC DIC Score factor score Presence of known underlying disorder No= 0 yes=2 Coagolation
More informationDisseminated intravascular coagulation (DIC) Dr. Klara Vezendi Szeged University Transfusiology Department
Disseminated intravascular coagulation (DIC) Dr. Klara Vezendi Szeged University Transfusiology Department Disseminated intravascular coagulation (DIC, consumptive coagulopathy) is a clinicopathologic
More informationApproach to bleeding disorders &treatment. by RAJESH.N General medicine post graduate
Approach to bleeding disorders &treatment by RAJESH.N General medicine post graduate 2 Approach to a patient of bleeding diathesis 1. Clinical evaluation: History, Clinical features 2. Laboratory approach:
More informationApproach to disseminated intravascular coagulation
Approach to disseminated intravascular coagulation Khaire Ananta Shankarrao 1, Anil Burley 2, Deshmukh 3 1.MD Scholar, [kayachikitsa] 2.Professor,MD kayachikitsa. 3.Professor and HOD,Kayachikitsa. CSMSS
More informationSysmex Educational Enhancement and Development No
SEED Coagulation Sysmex Educational Enhancement and Development No 2 2016 An approach to the bleeding patient The purpose of this newsletter is to provide an overview of the approach to the bleeding patient
More informationBlood coagulation and fibrinolysis. Blood clotting (HAP unit 5 th )
Blood coagulation and fibrinolysis Blood clotting (HAP unit 5 th ) Vessel injury Antithrombogenic (Favors fluid blood) Thrombogenic (Favors clotting) 3 Major systems involved Vessel wall Endothelium ECM
More informationTransfusion in major bleeding: new insights. Gert Poortmans
Transfusion in major bleeding: new insights Gert Poortmans Trauma Cardiac Surgery Major Surgery with ongoing blood loss Burn Surgery Lethal Triad Polytransfusion: definitions Coagulation Coagulopathy of
More informationACQUIRED COAGULATION ABNORMALITIES
ACQUIRED COAGULATION ABNORMALITIES ACQUIRED COAGULATION ABNORMALITIES - causes 1. Liver disease 2. Vitamin K deficiency 3. Increased consumption of the clotting factors (disseminated intravascular coagulation
More informationInternal Quality Control in the Haemostasis laboratory. Dr Steve Kitchen Sheffield Haemophilia and Thrombosis centre & UK NEQAS Blood Coagulation
Internal Quality Control in the Haemostasis laboratory Dr Steve Kitchen Sheffield Haemophilia and Thrombosis centre & UK NEQAS Blood Coagulation Why do we need Quality control? Philadelphia Enquirer Aug
More informationDISSEMINATED INTRAVASCULAR COAGULATION (DIC) Pichika Chantrathammachart MD Division of Hematology, Department of Medicine Ramathibodi Hospital
DISSEMINATED INTRAVASCULAR COAGULATION (DIC) Pichika Chantrathammachart MD Division of Hematology, Department of Medicine Ramathibodi Hospital Disseminated intravascular coagulation (DIC) Disseminated
More informationActive date July Ratification date: Review date January 2014 Applies to: Staff managing patients on warfarin. Exclusions:
Guideline Title: Guidelines for the management of warfarin reversal [key words : Beriplex, Octaplex, PCC, vitamin K, anticoagulant, anticoagulation] Authors: Dr Sarah Allford, Consultant Haematologist
More informationCitation for published version (APA): Müller, M. C. A. (2014). Coagulopathy and plasma transfusion in critically ill patients
UvA-DARE (Digital Academic Repository) Coagulopathy and plasma transfusion in critically ill patients Müller, Marcella Link to publication Citation for published version (APA): Müller, M. C. A. (2014).
More informationChapter 5. Recombinant factor VIIa improves clot formation but not fibrinolytic potential in patients with cirrhosis and during liver transplantation
Recombinant factor VIIa improves clot formation but not fibrinolytic potential in patients with cirrhosis and during liver transplantation Ton Lisman, Frank W.G. Leebeek 1, Karina Meijer 2, Jan van der
More informationThursday, February 26, :00 am. Regulation of Coagulation/Disseminated Intravascular Coagulation HEMOSTASIS/THROMBOSIS III
REGULATION OF COAGULATION Introduction HEMOSTASIS/THROMBOSIS III Regulation of Coagulation/Disseminated Coagulation necessary for maintenance of vascular integrity Enough fibrinogen to clot all vessels
More informationMajor Haemorrhage Protocol. Commentary
Hairmyres Hospital Monklands Hospital Wishaw General Hospital Major Haemorrhage Protocol Commentary N.B. There is a separate NHSL protocol for the Management of Obstetric Haemorrhage Authors Dr Tracey
More informationCME/SAM. Influence of Coagulation and Anticoagulant Factors on Global Coagulation Assays in Healthy Adults
Coagulation and Transfusion Medicine / Global Coagulation Assays and Coagulation Proteins Influence of Coagulation and Anticoagulant Factors on Global Coagulation Assays in Healthy Adults Seon Young Kim,
More informationMechanisms of Trauma Coagulopathy. Dr B M Schyma Changi General Hospital Singapore
Mechanisms of Trauma Coagulopathy Dr B M Schyma Changi General Hospital Singapore HAEMORRHAGE A continued cause of PREVENTABLE death. 24% of trauma patients are coagulopathic on arrival 1 56% of severe
More informationGeneral approach to the investigation of haemostasis. Jan Gert Nel Dept. of Haematology University of Pretoria 2013
General approach to the investigation of haemostasis Jan Gert Nel Dept. of Haematology University of Pretoria 2013 Clinical reasons to investigate haemostasis Investigating a clinically suspected bleeding
More informationDIAGNOSTIC TESTING IN PATIENT BLOOD MANAGEMENT PROGRAMS
DIAGNOSTIC TESTING IN PATIENT BLOOD MANAGEMENT PROGRAMS The Role of Diagnostic Point-of-Care Testing Diagnostic testing is an essential component of Patient Blood Management. The accurate assessment of
More informationIntraoperative haemorrhage and haemostasis. Dr. med. Christian Quadri Capoclinica Anestesia, ORL
Intraoperative haemorrhage and haemostasis Dr. med. Christian Quadri Capoclinica Anestesia, ORL Haemostasis is like love. Everybody talks about it, nobody understands it. JH Levy 2000 Intraoperative Haemorrhage
More informationAssessing thrombocytopenia in the intensive care unit: The past, present, and future
Assessing thrombocytopenia in the intensive care unit: The past, present, and future Ryan Zarychanski MD MSc FRCPC Sections of Critical Care and of Hematology, University of Manitoba Disclosures FINANCIAL
More informationTransfusion Requirements and Management in Trauma RACHEL JACK
Transfusion Requirements and Management in Trauma RACHEL JACK Overview Haemostatic resuscitation Massive Transfusion Protocol Overview of NBA research guidelines Haemostatic resuscitation Permissive hypotension
More informationThromboelastography Use in the Perioperative Transfusion Management of a Patient with Hemophilia A Undergoing Liver Transplantation
Open Journal of Organ Transplant Surgery, 2013, 3, 13-17 http://dx.doi.org/10.4236/ojots.2013.31003 Published Online February 2013 (http://www.scirp.org/journal/ojots) Thromboelastography Use in the Perioperative
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/37409 holds various files of this Leiden University dissertation Author: Engbers, Marissa Title: Conventional and age-specific risk factors for venous thrombosis
More informationHaemostasis & Coagulation disorders Objectives:
Haematology Lec. 1 د.ميسم مؤيد علوش Haemostasis & Coagulation disorders Objectives: - Define haemostasis and what are the major components involved in haemostasis? - How to assess the coagulation status?
More informationEffective Date: Approved by: Laboratory Director, Jerry Barker (electronic signature)
1 of 5 Policy #: 702 (PHL-702-05) Effective Date: 9/30/2004 Reviewed Date: 8/1/2016 Subject: TRANSFUSION GUIDELINES Approved by: Laboratory Director, Jerry Barker (electronic signature) Approved by: Laboratory
More informationHEMOSTASIS Quality Time saving Economy Practicability Quality assurance Precision
Quality Time saving Economy Practicability Quality assurance Precision exclusive distributor of for France, Netherlands, Belgium and Luxembourg List of frozen reagents In 1992, Precision BioLogic began
More informationTHROMBOTIC DISORDERS: The Final Frontier
THROMBOTIC DISORDERS: The Final Frontier Jeffrey I. Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis Heart & Stroke Foundation/ J.F.
More informationAppendix 3 PCC Warfarin Reversal
Appendix 3 PCC Warfarin Reversal Reversal of Warfarin and Analogues 1. Principle of Procedure Guidelines for the Reversal of Oral-anticoagulation in the Event of Life Threatening Haemorrhage Prothrombin
More informationManagement of Challenging Bleeding: Patients with Coagulopathy
Management of Challenging Bleeding: Patients with Coagulopathy Joanne E Joseph Department of Haematology, SydPath St Vincent s Hospital University of NSW Sydney First and foremost.. It helps to know which
More informationClinical Study Procoagulant and Anticoagulant Factors in Childhood Hypothyroidism
International Endocrinology Volume 2012, Article ID 156854, 4 pages doi:10.1155/2012/156854 Clinical Study Procoagulant and Anticoagulant Factors in Childhood Hypothyroidism Nevin Kilic, 1 Yildiz Dallar,
More informationInherited Thrombophilia Testing. George Rodgers, MD, PhD Kristi Smock MD
Inherited Thrombophilia Testing George Rodgers, MD, PhD Kristi Smock MD Prevalence and risk associated with inherited thrombotic disorders Inherited Risk Factor % General Population % Patients w/ Thrombosis
More informationThe Egyptian Journal of Hospital Medicine (July 2018) Vol. 72 (9), Page
The Egyptian Journal of Hospital Medicine (July 2018) Vol. 72 (9), Page 5210-5214 The Utility of Fibrinogen/C-reactive protein Ratio versus D-dimer and Fibrin Degradation Product in Diagnosis of Overt
More informationPREDLOG SMERNIC ZA KLINIČNO UPORABE SVEŽE ZMRZNJENE PLAZME Guidelines for clinical use of FFP proposal
PREDLOG SMERNIC ZA KLINIČNO UPORABE SVEŽE ZMRZNJENE PLAZME Guidelines for clinical use of FFP proposal Dragoslav Domanovič, MD. PhD. Blood transfusion centre of Slovenia, Ljubljana FFP - definition Fresh
More informationPart IV Antithrombotics, Anticoagulants and Fibrinolytics
Part IV Antithrombotics, Anticoagulants and Fibrinolytics "The meaning of good and bad, of better and worse, is simply helping or hurting" Emerson Chapter 16: Blood Coagulation and Fibrinolytic System
More informationHemostasis and thrombosis in patients with liver disease. Ton Lisman, Dept Surgery, UMC Groningen, The Netherlands
Hemostasis and thrombosis in patients with liver disease Ton Lisman, Dept Surgery, UMC Groningen, The Netherlands Importance of the liver in hemostasis Synthesis of Coagulation factors Fibrinolytic proteins
More informationBeyond Clotting Time Clot Waveform Analysis (CWA)
Beyond Clotting Time Clot Waveform Analysis (CWA) DR CHUEN WEN TAN CONSULTANT DEPARTMENT OF HAEMATOLOGY SINGAPORE GENERAL HOSPITAL FELLOW ANZAC RESEARCH INSTITUTE HAEMATOLOGY, CONCORD HOSPITAL Outline
More informationInsights on the Quality of Coagulation Testing
Insights on the Quality of Coagulation Testing Piet Meijer ECAT Foundation The Netherlands No conflicts of interest HAEMOSTATIC BALANCE BLEEDING HAEMOSTATIC BALANCE THROMBOSIS HAEMOSTATIC BALANCE Thrombosis
More informationEMSS17: Bleeding patients course material
EMSS17: Bleeding patients course material Introduction During the bleeding patients workshop at the Emergency Medicine Summer School 2017 (EMSS17) you will learn how to assess and treat bleeding patients
More informationBlood clotting. Subsequent covalent cross-linking of fibrin by a transglutaminase (factor XIII) further stabilizes the thrombus.
Blood clotting It is the conversion, catalyzed by thrombin, of the soluble plasma protein fibrinogen (factor I) into polymeric fibrin, which is deposited as a fibrous network in the primary thrombus. Thrombin
More informationUNIT VI. Chapter 37: Platelets Hemostasis and Blood Coagulation Presented by Dr. Diksha Yadav. Copyright 2011 by Saunders, an imprint of Elsevier Inc.
UNIT VI Chapter 37: Platelets Hemostasis and Blood Coagulation Presented by Dr. Diksha Yadav Hemostasis: Prevention of Blood Loss Vascular constriction Formation of a platelet plug Formation of a blood
More informationThe effect of corn trypsin inhibitor and inhibiting antibodies for FXIa and FXIIa on coagulation of plasma and whole blood
Journal of Thrombosis and Haemostasis, 12: 1678 1686 DOI: 1.1111/jth.1277 ORIGINAL ARTICLE The effect of corn trypsin inhibitor and inhibiting antibodies for FXIa and FXIIa on coagulation of plasma and
More informationDubbi e certezze nella gestione delle emorragie con metodiche point-of-care
Sessione Educazionale 4 : Gestione del paziente emorragico Dubbi e certezze nella gestione delle emorragie con metodiche point-of-care P. Simioni Università di Padova hemostasis Vascular phase Platelet
More informationMASSIVE TRANSFUSION DR.K.HITESH KUMAR FINAL YEAR PG DEPT. OF TRANSFUSION MEDICINE
MASSIVE TRANSFUSION DR.K.HITESH KUMAR FINAL YEAR PG DEPT. OF TRANSFUSION MEDICINE CONTENTS Definition Indications Transfusion trigger Massive transfusion protocol Complications DEFINITION Massive transfusion:
More informationChapter 1. General introduction
Chapter 1 General introduction 8 Haemostasis All organs and tissues of higher organisms are provided with nutrients and oxygen through the bloodstream. The bloodstream is an extensive vascular system that
More informationCoagulation an Overview Dr.Abdolreza Abdolr Afrasiabi Thal assem a & Heamophili hilia G ene i tic R esearc C en er Shiraz Medical Medic University
In The Name God Coagulation an Overview Dr.Abdolreza Afrasiabi Thalassemia & Heamophilia Genetic Research hcenter Shiraz Medical University Bleeding Clotting Hemostasis Review of platelet function Platelets
More informationHEME 10 Bleeding Disorders
HEME 10 Bleeding Disorders When injury occurs, three mechanisms occur Blood vessels Primary hemostasis Secondary hemostasis Diseases of the blood vessels Platelet disorders Thrombocytopenia Functional
More informationHuman coagulation factor Xa, FXa ELISA Kit
Human coagulation factor Xa, FXa ELISA Kit Catalog No: E1613h 96 Tests Operating instruction www.eiaab.com FOR RESEARCH USE ONLY; NOT FOR THERAPEUTIC OR DIAGNOSTIC APPLICATIONS! PLEASE READ THROUGH ENTIRE
More informationWhen should I transfuse platelets and plasma for children? Dr Liz Chalmers. Consultant Paediatric Haematologist Royal Hospital for Children Glasgow
When should I transfuse platelets and plasma for children? Dr Liz Chalmers Consultant Paediatric Haematologist Royal Hospital for Children Glasgow When should I transfuse platelets and plasma in children?
More informationHematology Review. CCRN exam. The Coagulation Cascade. The Coagulation Cascade. Components include: Intrinsic pathway Extrinsic pathway Common pathway
CCRN exam Hematology Review CCRN Review October 2013 Department of Critical Care Nursing Hematology is 2% of the exam Focus on coagulation cascade, DIC, and HIT Anatomy of the hematologic system Bone marrow
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) CORE SPC FOR HUMAN PROTHROMBIN COMPLEX PRODUCTS (CPMP/BPWG/3735/02)
European Medicines Agency Human Medicines Evaluation Unit London, 21 October 2004 Corrigendum, 18 November 2004 CPMP/BPWG/3735/02 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) CORE SPC FOR HUMAN
More informationMohammadreza Tabatabaei IBTO COAG LAB
Tests for the Evaluation of Lupus Anticoagulants t Mohammadreza Tabatabaei MSc Hematology blood bank MSc Hematology blood bank IBTO COAG LAB Lupus Anticoagulants General Background Lupus anticoagulants
More informationThis slide belongs to iron lecture and it is to clarify the iron cycle in the body and the effect of hypoxia on erythropoitein secretion
This slide belongs to iron lecture and it is to clarify the iron cycle in the body and the effect of hypoxia on erythropoitein secretion Topics of today lectures: Hemostasis Meaning of hemostasis Mechanisms
More informationTitle. Author(s)Hayakawa, Mineji; Gando, Satoshi; Hoshino, Hirokatsu. CitationClinical and Applied Thrombosis/Hemostasis, 13(1): 6. Issue Date
Title A Prospective Comparative Study of Three Sets of Cri vs Japanese Criteria Author(s)Hayakawa, Mineji; Gando, Satoshi; Hoshino, Hirokatsu CitationClinical and Applied Thrombosis/Hemostasis, 13(1):
More informationPICT ANTICOAGULANT MONITORING 1. PEFAKIT PICT. Clotting Assay. PEFAKIT PiCT. PEFAKIT PICT Calibrators UFH. PEFAKIT PICT Controls UFH
1 2 3 4 PEFAKIT PiCT PEFAKIT PICT Calibrators UFH PEFAKIT PICT Controls UFH PEFAKIT PICT Calibrators LMWH Clotting Assay PICT 1. PEFAKIT PICT Package size 8-505-01 kit 80 3 vials of PiCT Activator (2mL)
More informationHemostasis in patients with acute kidney injury secondary to acute liver failure
clinical investigation http://www.kidney-international.org & 2013 International Society of Nephrology see commentary on page 22 Hemostasis in patients with acute kidney injury secondary to acute liver
More informationNew Advances in Transfusion EM I LY CO BERLY, M D
New Advances in Transfusion EM I LY CO BERLY, M D TRANSFUSI ON M EDI CI NE FELLO W VANDERBI LT UNI VERSITY Objectives To discuss the terminology, components, transfusion risks, and dosing guidelines for
More informationM B Garvey. University of Toronto
Do I really need that test??? M B Garvey Professor Emeritus University of Toronto St Michael s Hospital No relevant conflicts of interest 1 HEMOSTASIS IS LIKE LOVE Everybody talks about it, nobody understands
More informationStability of prothrombin time and activated partial thromboplastin time tests under different storage conditions
Clinica Chimica Acta 300 (2000) 13 21 www.elsevier.com/ locate/ clinchim Stability of prothrombin time and activated partial thromboplastin time tests under different storage conditions L.V. Rao *, A.O.
More informationChapter 3. Haemostatic abnormalities in patients with liver disease
Chapter 3 Haemostatic abnormalities in patients with liver disease Ton Lisman, Frank W.G. Leebeek 1, and Philip G. de Groot Thrombosis and Haemostasis Laboratory, Department of Haematology, University
More informationBlood Transfusion Guidelines in Clinical Practice
Blood Transfusion Guidelines in Clinical Practice Salwa Hindawi Director of Blood Transfusion Services Associate Professor in Haematology and Transfusion Medicine King Abdalaziz University, Jeddah Saudi
More informationBASIC LIVER, PANCREAS, AND BILIARY TRACT. An Imbalance of Pro- vs Anti-Coagulation Factors in Plasma From Patients With Cirrhosis
GASTROENTEROLOGY 2009;137:2105 2111 BASIC LIVER, BILIARY TRACT An Imbalance of Pro- vs Anti-Coagulation Factors in Plasma From Patients With Cirrhosis ARMANDO TRIPODI,* MASSIMO PRIMIGNANI, VEENA CHANTARANGKUL,*
More informationApproach To A Bleeding Patient
ABDUL MAJEED, RAHUL RAJEEV REVIEW ARTICLE INTRODUCTION Hemostasis is the process of forming clots in the walls of damaged blood vessels and preventing blood loss while maintaining blood in a fluid state
More informationGroupe d Intérêt en Hémostase Périopératoire
How do I treat massive bleeding? Red blood cell / plasma / platelet ratio and massive transfusion protocols Anne GODIER Service d Anesthésie-Réanimation Hopital Cochin Paris Groupe d Intérêt en Hémostase
More informationProlonged clot lysis time increases the risk of a first but not recurrent venous thrombosis
research paper Prolonged clot lysis time increases the risk of a first but not recurrent venous thrombosis Alev Karasu, 1 Trevor P. Baglin, 2 Roger Luddington, 2 Caroline A. Baglin 2 and Astrid van Hylckama
More informationIntroduction. Keywords: antithrombin, hemophilia, newborn, thrombin generation, tissue factor, tissue factor pathway inhibitor.
Journal of Thrombosis and Haemostasis, 4: 171 177 ORIGINAL ARTICLE Thrombin generation in factor VIII-depleted neonatal plasma: nearly normal because of physiologically low antithrombin and tissue factor
More informationBLEEDING DISORDERS Simple complement:
BLEEDING DISORDERS Simple complement: 1. Select the statement that describe the thrombocytopenia definition: A. Marked decrease of the Von Willebrandt factor B. Absence of antihemophilic factor A C. Disorder
More informationSchematic Of Heparin Induced Thrombocytopenia Platelet Count
Schematic Of Heparin Induced Thrombocytopenia Platelet Count Normal IgG and IgG2 differentially inhibit HIT antibody-dependent platelet activation that platelet counts were lower in FcγRIIA 131RR patients
More informationProthrombin (Human) ELISA Kit
Prothrombin (Human) ELISA Kit Catalog Number KA0496 96 assays Version: 04 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Background... 3 Principle of the Assay... 3 General
More informationConsultative Coagulation How to Effectively Answer Common Questions About Hemostasis Testing Session #5000
Consultative Coagulation How to Effectively Answer Common Questions About Hemostasis Testing Session #5000 Dorothy M. (Adcock) Funk, M.D. Karen A. Moser, M.D. Esoterix Coagulation September 20, 2013 Disclosures
More informationUse of Prothrombin Complex Concentrate to Reverse Coagulopathy Rio Grande Trauma Conference
Use of Prothrombin Complex Concentrate to Reverse Coagulopathy Rio Grande Trauma Conference John A. Aucar, MD, MSHI, FACS, CPE EmCare Acute Care Surgery Del Sol Medical Center Associate Professor, University
More informationCh. 45 Blood Plasma proteins, Coagulation and Fibrinolysis Student Learning Outcomes: Describe basic components of plasma
Chapt. 45 Ch. 45 Blood Plasma proteins, Coagulation and Fibrinolysis Student Learning Outcomes: Describe basic components of plasma Inheritance of X-linked gene for Factor VIII hemophilia A Explain the
More informationPHASES OF HAEMOSTASIS
HAEMOSTASIS Maintains the integrity of a closed, highpressure circulatory system after vascular damage Vessel Wall Injury events in the vessel wall and in the blood which seal breach Delicate balance exists
More informationTRAUMA RESUSCITATION. Dr. Carlos Palisi Dr. Nicholas Smith Liverpool Hospital
TRAUMA RESUSCITATION Dr. Carlos Palisi Dr. Nicholas Smith Liverpool Hospital First Principles.ATLS/EMST A- Airway and C-spine B- Breathing C- Circulation and Access D- Neurological deficit E- adequate
More informationBleeding, Coagulopathy, and Thrombosis in the Injured Patient
Bleeding, Coagulopathy, and Thrombosis in the Injured Patient June 7, 2008 Kristan Staudenmayer, MD Trauma Fellow UCSF/SFGH Trauma deaths Sauaia A, et al. J Trauma. Feb 1995;38(2):185 Coagulopathy is Multi-factorial
More information1990s DTI. 1980s LMWH
1930s Heparin Parenteral Narrow therapeutic index Unpredictable Monitoring HIT Bleeding risk 1950s Warfarin Narrow therapeutic index Unpredictable Drug interactions Monitoring Bleeding risk 1980s LMWH
More informationUniversity of Groningen. Hemostasis and anticoagulant therapy in liver diseases Potze, Wilma
University of Groningen Hemostasis and anticoagulant therapy in liver diseases Potze, Wilma IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Shima M, Hanabusa H, Taki M, et al. Factor VIII mimetic function
More informationCrossmatching and Issuing Blood Components; Indications and Effects.
Crossmatching and Issuing Blood Components; Indications and Effects. Alison Muir Blood Transfusion, Blood Sciences, Newcastle Trust Topics Covered Taking the blood sample ABO Group Antibody Screening Compatibility
More informationEmergency Blood and Massive Transfusion: The Surgeon s Perspective. Transfusion Medicine Update September 16 17, 2009
Transfusion Medicine Update September 16 17, 2009 Mandip S. Atwal, D.O. FACOS Carl M. Pesta, D.O. FACOS Agenda History Hemorrhagic shock Transfusion is Bad Transfusion Prevention Transfusion The Red Chest
More informationImportant Considera/ons for Coagula/on Tests on Children and Neonates
Important Considera/ons for Coagula/on Tests on Children and Neonates Cindy Neunert, MD MSCS Associate Professor Pediatric Hematology/Oncology/Bone Marrow Transplant Columbia University Medical Center
More informationBlood transfusion. Dr. J. Potgieter Dept. of Haematology NHLS - TAD
Blood transfusion Dr. J. Potgieter Dept. of Haematology NHLS - TAD General Blood is collected from volunteer donors >90% is separated into individual components and plasma Donors should be: healthy, have
More informationBleeding and Haemostasis. Saman W.Boskani HDD, FIBMS Maxillofacial Surgeon
Bleeding and Haemostasis Saman W.Boskani HDD, FIBMS Maxillofacial Surgeon 1 Beeding Its escaping or extravasation of blood contents from blood vessels Types: - Arterial - Venous - Capillary Differences
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Acute lung injury (ALI) transfusion-related, 363 372. See also Transfusion-related acute lung injury (TRALI) ALI. See Acute lung injury
More informationEffects of preanalytical frozen storage time and temperature on screening coagulation tests and factors VIII and IX activity
www.nature.com/scientificreports Received: 8 February 2017 Accepted: 30 August 2017 Published: xx xx xxxx OPEN Effects of preanalytical frozen storage time and temperature on screening coagulation tests
More informationBiochemical Reaction Networks and Blood Clotting
Biochemical Reaction Networks and Blood Clotting Yasmeen Hussain, Aaron Fogelson Abstract Following an injury to the walls of a blood vessel, platelet aggregation and blood coagulation are induced. Through
More informationFluorogenic Substrates
PENTAPHARM Fluorogenic Substrates Pentapharm Ltd. offers a broad spectrum of fluorogenic peptide substrates for research, inprocess and quality control, employing the fluorogenic group AMC (7-Amino-4-methylcoumarin).
More information